Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
14 April 2025 | Story Martinette Brits | Photo Kaleidoscope Studios
NAS Medal Winners
The four medal winners from the Faculty of Natural and Agricultural Sciences are from left: Christine Rossouw, Philippus Kotzé, Michail Cloete, and Jocelyne Smith.

At the University of the Free State (UFS) April graduation ceremonies, the Faculty of Natural and Agricultural Sciences proudly celebrated the success of 1484 graduates – each one marking a milestone of academic excellence. Among these achievements, four standout students were awarded top honours for their exceptional academic performance.

Jocelyne Smith graduated with a Bachelor of Science Honours in Data Science and received both the prestigious Senate Medal - awarded for the highest weighted average across all UFS faculties - and the Dean’s Medal for achieving the top results in a bachelor honours degree within the faculty. 

Joining her in academic distinction were Christine Rossouw, Philippus Kotzé, and Michail Cloete, who each received a Dean’s Medal for outstanding results in their respective qualifications. Rossouw earned top marks in a three-year bachelor's degree, Kotzé in a four-year bachelor's degree, and Cloete for a master’s degree.

 

From setbacks to success: Jocelyne Smith’s unexpected path to excellence

Jocelyne Smith never intended to pursue Data Science. Her dream was to study medicine and make a meaningful difference in her community. However, when things did not go as planned, she found herself at a difficult crossroads. “I was devastated and unsure what to do next,” she recalls. 

A timely suggestion from Prof Eduan Kotzé introduced her to Data Science – a field she had never considered but soon came to love. Now pursuing a master’s degree, Smith says receiving the Senate and Dean’s Medals was a complete surprise. “I just tried to do my best every day,” she says. “Receiving the medals is a reminder that even when life takes an unexpected turn, the destination can still be extraordinary.”

Her journey has been one of perseverance, long nights of study, and a commitment to community and helping others understand complex material. “Helping others deepened my own understanding and made the experience more meaningful,” she adds. 

Looking ahead, Smith aims to harness Artificial Intelligence (AI) to revolutionise education in South Africa. “AI can make a real difference if used correctly - especially in education,” she explains. Her research focuses on challenging outdated systems and empowering individuals through innovative, practical technology.

 

Designing for impact: Michail Cloete’s award-winning architectural journey

For Michail Cloete, architecture is not just about buildings – it is about problem-solving and creating meaningful spaces. Inspired by his father’s work, he pursued architecture with clarity of purpose and deep-rooted passion.

“My academic success was driven by balance, consistency, and a genuine passion for impactful design,” he says. That mindset paid off, earning him the Dean’s Medal for best performance in a master’s degree.

Cloete views the medal not only as personal recognition but also as a tribute to those who supported him. “It reflects the collective effort – the love, support, and sacrifices of my family and friends,” he shares. 

Looking forward, Cloete hopes to join an architectural firm that creates spaces with lasting impact, continuing a journey grounded in creativity, commitment, and thoughtful design.

 

Rooted in passion: Philippus Kotzé recognised for academic excellence

A deep love for farming and a growing interest in agriculture led Philippus Kotzé to pursue a degree in Animal Sciences. His approach to his studies was straightforward: “I went into the course to learn as much as I could. Good marks were just a welcome side-effect.”

Kotzé’s self-discipline, coupled with encouragement of classmates and lecturers, helped him navigate the demands of a four-year degree – resulting in the Dean’s Medal for academic excellence. 

“There is a saying, ‘Vele hande maak ligte werk.’ For us, the lights were on for four straight years,” he jokes, crediting the collective effort of his support network for his success. 

Now farming full-time, Kotzé aims to grow and diversify within the agricultural sector – bringing the same focused dedication to his career that defined his academic journey. 

 

Bright minds, bold dreams: Christine Rossouw shines in science

Driven by a love for problem-solving and a fascination with how things work, Christine Rossouw found her perfect fit in the sciences. “I love experimenting and figuring things out,” she says. Her curiosity and determination helped her achieve top marks in a Bachelor of Science degree specialising in Chemistry and Physics, earning her the Dean’s Medal for the best results in a three-year bachelor’s degree.  

Rossouw credits her success to maintaining a healthy balance. “Work hard, stay curious, and make time to recharge,” she advises. For her academic achievement is just the beginning - a stepping stone toward big ambitions, that include designing fireworks, advancing green energy, and improving plastic recycling.

Although the full weight of the award is still sinking in, Rossouw is already looking to the future – one that promises to be as bright as her ideas.

 

Words of wisdom: Emmie Pietersen’s message to graduates 

Emmie Pietersen, Head of Strategy and Programme Development at Peritum Agri Institute, delivered a heartfelt message to graduates at all three sessions on Thursday, 10 April. Drawing from the lessons that continue to shape her own life, she urged graduates to embrace each day as a gift – a reminder that every moment presents both a chance and a choice. 

“Your presence is your brand,” she said, encouraging graduates to carry themselves with both confidence and humility. True success, she explained, lies in the ability to prioritise, to plan with intention, foster meaningful partnerships, and persevere - because failure only happens when we stop trying.

In closing, she shared a powerful message she once gave to her son: “You were fearfully and wonderfully made. Grow your career with courage, but tread softly. Make us Kovsies proud.”

 

 

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept